NCT03299829View on ClinicalTrials.gov

A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients

CompletedOBSERVATIONAL
Enrollment

48

Participants

Timeline

Start Date

January 10, 2018

Primary Completion Date

June 30, 2019

Study Completion Date

December 30, 2019

Conditions
Trientine Treatment for Wilson's Disease
Interventions
DRUG

Trientine

Trientine is a chelating agent for removing the copper from the body

Trial Locations (1)

333

Chang Gung Memorial Hospital, Linkou, Taoyuan

Sponsors

Lead Sponsor

Excelsior
All Listed Sponsors
lead

Excelsior

INDUSTRY